- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Can Low-Dose CT Have an Impact in Diagnosing Bone Metastasis in Patients with Prostate Cancer?
In a study of 601 patients with prostate cancer, researchers found that only one patient with extensive metastasis was falsely diagnosed as non-metastatic on whole-body, low-dose computed tomography (CT) by reviewing radiologists.
For the detection of osteo-metastasis in patients with prostate cancer, whole-body computed tomography (CT) demonstrated sensitivity ranging between 81 to 89.4 percent and specificity ranging between 96.6 to 98.5 percent, according to new research.
For the study, recently published in Insights into Imaging, researchers examined the use of whole-body, low-dose CT for the diagnosis of osteo-metastasis in 601 patients (mean age of 68.7) with prostate cancer. According to the study, 35.1 percent of the cohort received imaging for initial staging and 64.9 percent had imaging to assess the extent of the disease after biochemical recurrence (BCR) of prostate cancer.
For the initial staging group, low-dose CT had a per-patient sensitivity rate ranging between 76.8 and 88.4 percent with specificity ranging between 98.6 and 99.3 percent. For patients with BCR, the researchers found a sensitivity range between 83.3 to 90 percent and a specificity rate between 95.6 to 98.6 percent for the reviewing radiologists. Overall, low-dose CT demonstrated an 81 to 89.4 percent sensitivity rate and a 96.6 to 98.5 percent specificity rate for osteo-metastasis in the study cohort, according to the authors.
In an analysis of metastatic lesions with underlying CT findings, the researchers found that lesion features such as size > 1 cm, cortical destruction, the presence of a soft tissue component and ill-defined borders were statistically associated with metastasis. (Images courtesy of Insights into Imaging.)
While previous research has shown higher sensitivity and specificity for 68Ga-PSMA PET/CT in detecting osteo-metastasis (see ref 9 in study), the study authors said whole-body, low-dose CT may provide a viable alternative that is less expensive and is more widely available than 68Ga-PSMA PET/CT.
“The high accuracy at the per-patient level indicated that CT could correctly diagnose the presence or absence of metastasis in most patients. However, in clinical management, both in staging and BCR conditions, it is important to know the burden of disease. In this issue, CT still had reliable performance, meaning most patients would receive the proper therapy,” wrote lead study author Mohammadreza Chavoshi, M.D., who is affiliated with the Department of Radiology at Shariati Hospital and the Tehran University of Medical Sciences in Iran, and colleagues.
The study authors noted that the per-lesion analysis for benign lesions with whole-body low-dose CT had significantly lower sensitivity (48.5 to 63.3 percent) as well as lower specificity (82.1 to 92.1 percent). The researchers also found that CT did not detect 30.8 percent of metastatic lesions in patients without extensive disease.
However, Chavoshi and colleagues noted that current CHAARTED and LATITUDE criteria for prostate cancer do not emphasize precision in determining the number and location of osteo-metastatic lesions as the treatment would be the same for patients deemed to be at high risk. They also noted that whole-body, low-dose CT had only one false diagnosis of a patient with extensive metastasis.
“In the initial staging of PCa patients based on the above-mentioned criteria, whole-body low-dose CT showed promising findings in terms of specificity and (positive predictive value), regardless of readers’ expertise. This means that the treatment approach would have been confidently adopted in the patients diagnosed with the high-burden disease,” noted Chavoshi and colleagues.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).
